Poster presentations

Poster presentations will be displayed for the duration of MTIS2026.

Presentations with an “EP” number will also be presented as short oral presentations.

P01/EP01 Patterns of headache-related healthcare utilization within the Norwegian adult population.

Dr Zhilwan Gadan1, Anette Tryti, Dr Maria Bengtson Argren, Dr Helene Engstrand, John-Anker Zwart, Bendik Slagsvold Winsvold

1University of Oslo, Department of Research and Innovation, Division of Clinical Neuroscience, Oslo, Norway

P02/EP02 Is there UK NHS inequity in migraine therapy access: Why where you live matters !!

Dr Brendan Davies1, Dr Ravindra Inaththappulige1,2, Claire Winstanley1, Carrie Poole1, Dr Amelia Panavila1, Irene Jacob1, Dr Kasun Athukoralage1

1Midlands Regional Headache clinic, University Hospital of North Midlands NHS Trust, Stoke on Trent, United Kingdom, 2Kings Headache Group, London, United Kingdom

P03/EP03 Headache Burden in The District General Hospital

Dr Rachel Jennings1, Dr Chloe Fisher1, Dr Mona Ghadiri-Sani2

1Mersey And West Lancashire Teaching Hospital, Prescot, United Kingdom, 2The Walton Centre, Liverpool, United Kingdom

P04/EP04 Early Exposure, Lasting Impact: Educational Outcomes of the Chicago Headache Center & Research Institute 8-Week Intensive Summer Research Internship Program in Headache and Migraine Medicine

Bradley Torphy1, Director of Research and Development Melody Smith1, Senior Clinical Research Coordinator Shania Cordon1, Clinical Research Coordinator Julia Panait1

1Chicago Headache Center & Research Institute, Chicago, United States

P05/EP05 Real-World Treatment Persistence and Adherence of Eptinezumab: Insights from Canadian Patient Support Program Data

Dr Joanna Bougie1, Scott White1, Dr Gustavo De Souza Luna2, Dr Marissa Lagman3, Dr Jonathan Gladstone4, Annamaria Dobrin5, Dr Sergey Muratov5, Calum Neish5

1Lundbeck Canada, Montréal, Canada, 2H. Lundbeck A/S, Copenhagen, Denmark, 3London Health Sciences Centre, London, Canada, 4Cleveland Clinic Canada, Toronto, Canada, 5IQVIA Canada, Mississauga, Canada

P06/EP06 Safety and tolerability of anti-PACAP monoclonal antibody bocunebart when co-administered with a gepant in participants with migraine

Amaal Starling1, Jessica Ailani2, Ioana Florea3, Charlotte Granhall3, Katrine Falkenberg3, Peter Eriksen3, Elin Löf3, Line Pickering-Boserup3, Ole Michael Lemming3, Bjørn Sperling3, Messoud Ashina4

1Mayo Clinic Arizona, USA, 2MedStar Georgetown University Hospital, USA, 3H. Lundbeck A/S, Denmark, 4Copenhagen University Hospital–Rigshospitalet, Denmark

P07/EP07 Real-World Impact of Eptinezumab Treatment on Migraine-Related Cognitive Symptoms in Participants in Whom ≥1 Prior CGRP-Targeted Therapy had Failed: 12-Month Results of a Prospective Study

Amaal J. Starling1, Richard B. Lipton2, Seema Soni-Brahmbhatt3, Stephane Regnier3, Susanne F. Awad4, S. Wald Grossman3, Emad Estemalik5

1Mayo Clinic Arizona, Scottsdale, USA, 2Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, USA, 3Lundbeck, Deerfield, USA, 4H. Lundbeck A/S, Copenhagen, Denmark, 5Cleveland Clinic Lerner College of Medicine, Cleveland, USA

P08/EP08 A systematic review and network meta-analysis of clinical effectiveness of pharmacological interventions for adults with episodic migraine

James Griffin1, Dr Seyran Naghdi1, Dr Callum Duncan2, Professor Erling Tronvik3, Anna Brown4, Andrew Cooklin1, Dr Gemma Pearce5, Dr Jasmine Bhogal1, Dr Samuel Frempong1, Professor Manjit Matharu6, Prof. Hema Mistry1

1Warwick Clinical Trials Unit, Coventry, United Kingdom, 2NHS Grampian, Aberdeen, United Kingdom, 3St Olavs Hospital, Trondheim , Norway, 4University of Birmingham, Birmingham, United Kingdom, 5Coventry University, Coventry, United Kingdom, 6University College London, London, United Kingdom

P09/EP09 Effect of Adding Atogepant to OnabotulinumtoxinA on Symptoms-Free Days: Results from a Phase 3, Multicenter, 24-Week Open-Label Study (UNCHAINED)

Andrew Blumenfeld1, Jennifer Robblee2, Elizabeth Seng3, Jia Bao4, Krisztian Nagy4, Jannette Contreras-De Lama4, Brett Dabruzzo4, Jonathan H. Smith4, Umer Najib5

1The Los Angeles Headache Center, Los Angeles, USA, 2Barrow Neurological Institute, Phoenix, USA, 3Albert Einstein College of Medicine, Bronx, USA, 4AbbVie, North Chicago, USA, 5Rockefeller Neuroscience Institute, West Virginia University, Morgantown, USA

P10/EP11 Propranolol Combined with Magnesium for the Prevention of Refractory Migraine and Improvement of Vascular Endothelial Function

Di Pu1

1The First Affiliated Hospital Of Chongqing Medical And Pharmaceutical College, Chongqing, China

P11 Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Final Results from a Phase 3, Open-Label, 156-Week, Long-Term Safety Extension Study

Messoud Ashina1,2, Sait Ashina3, Cristina Tassorelli4,5, Peter J. Goadsby6,7, Soo-Jin Cho8, Rebeka Man9, Hua Guo9, Eric B. Cohen9, Krisztian Nagy9, Jonathan H. Smith9

1Danish Headache Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, 2University of Copenhagen, Copenhagen, Denmark, 3Harvard Medical School, Boston, USA, 4University of Pavia, Pavia, Italy, 5IRCCS Mondino Foundation, Pavia, Italy, 6King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, 7King’s College London, London, UK, 8Hallym University College of Medicine, Hwaseong, Korea, 9AbbVie, North Chicago, USA

P12 Real-world impact of eptinezumab on migraine burden and participant-reported outcomes in adults with migraine in whom ≥1 prior CGRP-targeted preventive therapy had failed: results of the 12-month INFUSE study

Amaal Starling1, Stephane Regnier2, Seema Soni-Brahmbhatt2, Susanne F. Awad3, S. Wald Grossman2, Damian Fiore2, Emad Estemalik4

1Mayo Clinic Arizona, Scottsdale, USA, 2Lundbeck, Deerfield, USA, 3H. Lundbeck A/S, Copenhagen, Denmark, 4Cleveland Clinic Lerner College of Medicine, Cleveland, USA

P13 Cost-effectiveness of preventive medications for episodic migraine: challenges for decision-makers

Prof. Hema Mistry1, James Griffin1, Dr Asmaa El-Banna1, Dr Samuel Frempong1, Dr Callum Duncan2, Professor Erling Tronvik3, Anna Brown4, Andrew Cooklin1, Dr Gemma Pearce5, Dr Seyran Naghdi1, Professor Manjit Matharu6

P14 Weight Loss With Atogepant Versus Topiramate: Post hoc Analysis of the Head-to-Head TEMPLE Trial

Dale S. Bond1, Peter J. Goadsby2,3, Stewart J. Tepper4, Christian Lampl5, Antoinette Maassen van den Brink6, Yingyi Liu7, Eric Cohen7, Krisztian Nagy7, Jonathan H. Smith7, Brett Dabruzzo7, b Lee Peterlin8,9

1Center for Obesity Research, Innovation and Education, Digestive Health Institute, Hartford Hospital/HealthCare, Hartford, USA, 2NIHR King’s Clinical Research Facility, King’s College London, London, UK, 3King Abdulla University of Science and Technology, Thuwal, Saudi Arabia, 4New England Institute for Neurology and Headache, Stamford, USA, 5Department of Neurology, Konventhospital Barmherzige Brüder Linz, Linz, Austria, 6Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, 7AbbVie, North Chicago, USA, 8Pennsylvania Headache Center, Camp Hill, USA, 9Penn State Health Milton S. Hershey Medical Center, Hershey, USA

P15/EP11 The National Audit of Migraine: Protocol for a UK-Wide Programme to Improve Migraine Care

Dr Thomas Canning1,2, Dr Rachael Kilner3,4,5, Dr Gareth Williams6, Dr Alexandru Dregan2, Dr Giorgio Lambru1,7, Maddi Murphey7, Dr Katy Monro8, Dr Brendan Davies9, Dr Gina Kennedy10, Dr Sophie Dorsey11, Dr Jane Andersson12,13, Susie Lagrata14, Dr Mona Ghandiri-San15, Dr Martin Harley16, Dr David Watson17, Dr Theodoros Mavridis18, Debbie Clifford19, Rob Music20, Dr Andreas Yiangou21,22, Dr Anna Andreou1,7

1Headache Research, Wolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology, and Neuroscience (IoPPN), King’s College London, London, United Kingdom, 2Department of Psychological Medicine, IoPPN, King’s College London, London, United Kingdom, 3King’s College Hospital NHS Foundation Trust, London, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 5Bromley GP Alliance Headache Clinic, London, United Kingdom, 6Wolfson Sensory, Pain and Regeneration Centre, IoPPN, King’s College London, London, United Kingdom, 7Headache and Facial Pain Service, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 8National Migraine Centre, London, United Kingdom, 9Neurology Department, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, 10South Tyneside and Sunderland NHS Trust, United Kingdom, 11Hull and East Yorkshire Hospitals NHS Trust, United Kingdom, 12Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Neurology Department, Cambridge, United Kingdom, 13Princess Alexandra Hospital NHS Trust, Neurology Department, Harlow, United Kingdom, 14University College London Hospitals NHS Foundation Trust, London, United Kingdom, 15The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom, 16Department of Neurology, Ulster Hospital, South Eastern Health and Social Care Trust, Northern Ireland, 17Department of Neurology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, 18Department of Neurology, Tallaght University Hospital, Dublin, Ireland, 19Independent lived experience expert, 20The Migraine Trust, London, United Kingdom, 21Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, 22University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

P16/EP12 Nurse-Led Digital Headache Care Pathway in Estonian Primary Care: A Multi-Year Patient and Specialist Satisfaction Study Using the digital Application

Triinu Niiberg-Pikksööt1,2, Mark Braschinsky1,2, Katrina Laks1, Martin Leiger1, Hans Kristian Amjärv1

1OÜ Migrevention, Tallinn, Estonia, 2University of Tartu, Tartu, Estonia

P17/EP13 Chronic Nitroglycerin Model of Migraine Triggers Acute Physiological and Sleep Changes in Rodents

Ms Rebecca Ortiz1, Jordan Johnson1, PhD Dmitri Yousef Yengej1, PhD Guido Faas1, Dr Andrew Charles1, Dr, PhD Sinifunanya Nwaobi1

1Department of Neurology, University of California Los Angeles, Goldberg Migraine Program, Los Angeles, USA

P18 Secondary Muscle Hypertonicity Induced by Inflammatory Lymph Nodes: An Underrecognized Contributor to Headache

Dr Rostyslav Bubnov1, Dr Lev Kalika2, Dr Grzegorz Pilecki3, Dr Zbigniew Pilecki3

1Clinical hospital Pheophania, Kyiv, Kyiv, Ukraine, 2New York Dynamic Neuromuscular Rehabilitation & Physical Therapy, New York, USA, New York, USA, 3Silesian Academy Clinic of Pediatric Orthopedics, Chorzow, Poland

P19 Examining Migraine Pathophysiology in an Ehlers-Danlos Rodent Model

Sharii Liang1, Rebecca Ortiz2, Surabhi Chinta1, Dr. Sinifunanya Nwaobi2

1Ucla Department of Neurology, Los Angeles, United States, 2UCLA Goldberg Migraine Program, David Geffen School of Medicine Department of Neurology, Los Angeles, United States

P20/EP14 Multimodal Characterization of Spreading Depolarizations in Mouse Models of Migraine

Dr Alejandro Labastida Ramirez1, Dr Robert Wykes1

11Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

P21/EP15 Migraine Subgroups Defined by Associated Symptoms and Alleviating Strategies: A Cross-Sectional Study of 3275 Patients with Episodic Migraine

Dr Gabriele Sebastianelli1, Dr. PhD Daniele Secci2, Dr. PhD Cherubino Di Lorenzo1, Dr. PhD Armando Perrotta3, Prof. Gianluca Coppola1, Dr. PhD Anna Ambrosini3

1Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Sapienza University of Rome, Rome, Italy, 2Department of Engineering and Architecture, University of Parma, Parma, Italy, 3Headache Clinic – IRCCS NEUROMED, Pozzilli, Italy

P22/EP16: Clinical and radiological features of idiopathic intracranial hypertension

Dr Nerudseggha Satkuru1, Prof. Ralph T. Schär2, PD Dr. med Levin Hänni2, Prof. Eike I. Piechowiak3, PD Dr. med. Tomas Dobrocky3, Dr. med. Hilary M. Grabe4, Prof. Franz Riederer1,6, Prof. Christoph J. Schankin1,5, Dr Adrian Scutelnic1

1Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 2Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 3Department of Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 4Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 5Department of Neurology, Bellevue Medical Group, Centre for Migraine and Headache, Zürich, Switzerland, 6University of Zurich, Faculty of Medicine, Zurich, Switzerland

P23/EP17 Medication-overuse headache in vestibular migraine

Dr Madeline Leadon1, Dr Surangi Mendis1

1University College London Hospitals NHS Foundation Trust, London, United Kingdom

P24/EP18 Treatment outcomes with rimegepant versus other acute migraine medications in the observational CONFIDENCE study

Peter Goadsby1,2, Richard Lipton3, Lucy Abraham4, Alexandre Urani5, Giorgio Lambru6, Patricia Pozo-Rosich7,8, Kristina Fanning9, Karin Hygge Blakeman10

1King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, 2King’s College London, London, United Kingdom, 3Montefiore Headache Center and Albert Einstein College of Medicine, Bronx, USA, 4Pfizer R&D UK Ltd, Tadworth, United Kingdom, 5Aptar Digital Health, Rueil Malmaison, France, 6The Headache and Facial Pain Service, Guy’s and St. Thomas’ NHS Foundation Trust, King’s College London, London, United Kingdom, 7Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain, 8Headache Research Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, 9MIST Research, Wilmington, United States, 10Pfizer AB., Stockholm, Sweden

P25/EP19 Timecourse of Efficacy of Atogepant for the Acute Treatment of Migraine: Results from the ECLIPSE Trial

Dr. Alexandra J Sinclair1,2, Dr. Elimor Brand-Schieber3, Dr. Isabel Pavao Martins4,5, Dr. Annelies Van Dycke6, Dr. Dagny Holle-Lee7, Mr. Lei Luo3, Dr. Karen Carr3, Dr. Gina Ahmadyar3, Dr. Gianluca Coppola8

1Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom, 2Department of Neurology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3AbbVie Inc., North Chicago, United States, 4Department of Neurosciences and Mental Health, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, 5Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 6Department of Neurology, General Hospital Sint-Jan Bruges, Brugge, Belgium, 7Department of Neurology, West German Headache and Vertigo Centre Essen, University of Essen, Essen, Germany, 8Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy

P26/EP20 Efficacy and safety of rimegepant for acute migraine treatment in Chinese patients with medication-overuse headache: a post-hoc analysis of a prospective real-world study

Dr Ye Ran1,2, Qian Zhao4, Dr. Su Hui1,2, Dr. Shuhua Zhang3, Dr. Zizi He1,2, Yu Liu4, Jiyue Yang5, Prof. Zhao Dong1,2, Prof. Shengyuan Yu1,2

11st Medical Center of Chinese PLA General Hospital, Beijing, China, 2International Headache Centre, Chinese PLA General Hospital, Beijing, China, 3Chongqing Medical University, Chongqing, China, 4Pfizer Inc, Beijing, China, 5Pfizer Inc, New York, USA

P27/EP21 Impact of Rimegepant on Anxiety Symptoms in Patients with Migraine: Interim Results from a Real-World Study

Dr Ye Ran1,2, Qian Zhao4, Dr. Su Hui1,2, Dr. Shuhua Zhang3, Dr. Zizi He1,2, Yu Liu4, Jiyue Yang5, Prof. Zhao Dong1,2, Prof. Shengyuan Yu1,2

P28 Efficacy and safety of zavegepant for the acute treatment of migraine in adults with nausea: pooled subgroup analysis of data from two phase 3 randomized controlled trials

Aarushi Suneja1, Shengyuan Yu2, Linda Mosher3, Robert Fountaine3, Jerry Yang4, Panpan Wang5, Jing Wang6, Samantha Sweeney4, Denise Chou7

1Cleveland Clinic, Cleveland, USA, 2Chinese PLA General Hospital, Beijing, China, 3Pfizer, Groton, USA, 4Pfizer, New York, USA, 5Pfizer R&D, Shanghai, China, 6Pfizer R&D, Beijing, China, 7Pfizer, Cambridge, USA

P29 Rimegepant for the treatment of perimenstrual migraine attacks in the real world: Findings from CONFIDENCE

Peter Goadsby1,2, Richard Lipton3, Todd Schwedt4, Alexandre Urani5, Giorgio Lambru6, Patricia Pozo-Rosich7,8, Kristina Fanning9, Lucy Abraham10, Karin Hygge Blakeman11

1King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, 2King’s College London, London, United Kingdom, 3Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, USA, 4Department of Neurology, Mayo Clinic, Scottsdale, USA, 5Aptar Digital Health, Rueil Malmaison, France, 6The Headache and Facial Pain Service, Guy’s and St. Thomas’ NHS Foundation Trust, Kings College London, London, United Kingdom, 7Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain, 8Headache Research Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, 9MIST Research, Wilmington, USA, 10Pfizer R&D UK Ltd, Tadworth, United Kingdom, 11Pfizer AB, Stockholm, Sweden

P30 Acute (Refractory) Migraine Treatment Service: Delivering Acute Migraine Care at Home Through a Virtual Ward Pathway

Ms Amanda Combes1

1East Sussex Healthcare Nhs Trust, Hastings, United Kingdom

P31/EP22 Zavegepant for Acute Treatment of Migraine Attacks: Concomitant Use with CGRP Targeting Preventive Medications

Prof. Todd Schwedt1, Dr Shane Root1, Duke Butterfield1, Dani Smith1, Michael Leonard1, Crystal Hayes1, Madeline Keane1, Chelsea Leroue2, Samantha Sweeney2

1Mayo Clinic, 2Pfizer,

P32/EP23 Early Post-Launch Real-World Effectiveness and Safety of Rimegepant for Acute Migraine in Japan

Dr Kuniko Ota1, Dr, PhD Daisuke Danno1, Dr Toshiki Matsumoto1, Dr Kenji Murakata1, Dr Hanako Sugiyama1, Dr, PhD Yoshihiro Kashiwaya1, Dr, PhD Shoji Kikui1, Dr, PhD Takao Takeshima1

1Tominaga Hospital, Osaka, Japan

P33/EP24 Patient-Reported Benefits of Atogepant in the Acute Treatment of Migraine: Patient Global Impression of Change, Satisfaction with Study Medication, and Health-Related Quality of Life in the ECLIPSE Trial

Dr. Takao Takeshima1, Dr. Gina Ahmadyar2, Colleen Castro2, Dr. Elimor Brand-Schieber2, Dr. Raquel Gil-Gouveia3,4, Mr. Lei Luo2, Dr. Cristina Tassorelli5,6, Dr. Mi Ji Lee7,8, Dr. Karen Carr2, Dr. Annelies Van Dycke9

1Headache Center and Department of Neurology, Tominaga Hospital, Osaka, Japan, 2AbbVie Inc., North Chicago, United States, 3Neurology Department, Hospital da Luz, Lisboa, Portugal, 4Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal, 5Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy, 6Headache Science & Neurorehabilitation Centre, IRCCS C. Mondino Foundation, Pavia, Italy, 7Department of Neurology, Seoul National University Hospital, Seoul, South Korea, 8Seoul National University College of Medicine, Seoul, South Korea, 9Department of Neurology, General Hospital Sint-Jan Bruges, Brugge, Belgium

P34/EP25 CORRELATE-UK Interim analysis: reported consistency of response to rimegepant in acute treatment of migraine in the first four attacks of a prospective real-world study

Grant O’Neil1, Dr Karina Nakajima2, Lucy Abraham3, Michelle C Johnston1, Sophie Kilpatrick1, Dr Charlene Cheong4, Carmen Petitjean4, Sam Llewellyn4, Dr Marc Randall5, Dr Rebecca Walker6, Dr Giorgio Lambru7

1Pfizer Ltd., Tadworth, United Kingdom, 2Pfizer, Inc., New York, United States, 3Pfizer R&D, Tadworth, United Kingdom, 4Vitaccess Ltd, London, United Kingdom, 5The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6The National Migraine Centre, London, United Kingdom, 7The Headache and Facial Pain Service, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

P35/EP26 Clinical Outcomes of Rimegepant Acute Treatment in Migraine: Impact on Headache Burden and Mood Status Over 24 Weeks

Dr Yan Li1, Dr. Zhexian Yang1, Dr. Liya Qiu1, Dr. Yuhu Zhang1

1Department of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Guangzhou, China

P36/EP27 Earlier Acute Treatment of Migraine Attacks With Atogepant Is Associated With Improved Clinical Outcomes: Results From the ECLIPSE Study Open-Label Extension

Dr. Håkan Ashina1,2, Dr. Messoud Ashina2,3, Dr. Elimor Brand-Schieber4, Dr. Rafaelle Ornello5, Dr. Jan Versijpt6, Dr. Yasuhiko Matsumori7, Dr. Gina Ahmadyar4, Julia Ma4, Dr. Karen Carr4, Dr. Peter J. Goadsby8,9

1Translational Research Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, 2Department of Neurology, Center for Discoveries in Migraine and Danish Headache Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, 3Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 4AbbVie Inc., North Chicago, USA, 5Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy, 6Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium, 7Sendai Headache and Neurology Clinic, Sendai, Japan, 8King Abdullah University of Science and Technology, Saudi Arabia, Thuwal, 9King’s College London, London, UK

P37/EP28 Efficacy of Elismetrep, a Selective, Oral TRPM8 Channel Blocker, as a Monotherapy and in Combination with Gepants or Triptans in Preclinical Models of Migraine

Dr Justine Kupferman, Raul Estrada, Dr. Robert Lovelett, Bernadette Bracken, Dr. Shirly Pinto

1Kallyope, New York, United States

P38/EP29 Effects of Rimegepant on Depressive Symptoms in Migraine Patients: An Interim Analysis of a Prospective Real-World Study

Dr Ye Ran1,2, Qian Zhao3, Dr. Su Hui1,2, Dr. Shuhua Zhang5, Dr. Zizi He1,2, Yu Liu3, Jiyue Yang4, Prof. Zhao Dong1,2, Prof. Shengyuan Yu1,2

11st Medical Center of Chinese PLA General Hospital, Beijing, China, 2International Headache Centre, Chinese PLA General Hospital, Beijing, China, 3Pfizer Inc, Beijing, China, 4Pfizer Inc, New York, USA, 5Chongqing Medical University, Chongqing, China

P39/EP30 Prescription or Supplement: What do clinicians use for first-line migraine prevention in children and adolescents?

Prof. Amy Gelfand1, Dr. Scott Powers2,3, Dr. Carlyn Patterson Gentile4,5, Professor Andrew Hershey2,3, Dr. Blanca Marquez de Prado5, Dr. Hannah Shapiro1, Leigh Ann Chamberlin2, Dr. Christina Szperka4,5

1UCSF, San Francisco, USA, 2Cincinnati Children’s Hospital Medical Center, 3University of Cincinnati College of Medicine, 4Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5Pediatric Headache Program, Children’s Hospital of Philadelphia, USA

P40/EP31 Brain freeze in migraine: a systematic review of cold-stimulus headache

Ms Floor Van Welie1, Theres Patzelt1, Dr. Irene de Boer1, Prof. Dr. Gisela Terwindt1

1Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands, 2Health, Medical and Neuropsychology Unit, Faculty of Social and Behavioral Sciences, Leiden University, Leiden, the Netherlands

P41/EP32 Real-world data from an international survey of people living with migraine: unmet needs, preventive medication use and drivers of discontinuation

Dr Katherine Sommer6, Elena Ruiz de la Torre1, Shirley Kessel2, Cristina Tassorelli3, Jack Schim4, Jessica Ailani5, Peter J. Goadsby7

1European Migraine and Headache Alliance, 2Miles for Migraine, Jericho, USA, 3University of Pavia, Pavia, Italy, 4The Neurology Center of Southern California, Carlsbad, USA, 5Medstar Georgetown University Hospital, Washington DC, USA, 6Ipsen, Cambridge, USA, 7King Abdullah University of Science and Technology, Saudi Arabia and King’s College London, London, UK

P42/EP33 Longitudinal shifts in migraine frequency: transition from chronic to episodic migraine in a pooled analysis of the PEARL and FINESSE studies

Messoud Ashina1,2, Gregor Broessner3, Cristina Tassorelli4,5, Charly Gaul6, Patricia Pozo-Rosich7, Lars Neeb8, Dr Paul J. Dorman9, Pinar Kokturk10, Xenia Hamann11, Hasan Akcicek10, Andreas Straube12

1Department of Neurology, Danish Headache Center, Copenhagen University Hospital–Rigshospitalet Glostrup, Copenhagen, Denmark, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, 4Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy, 5IRCCS C. Mondino Foundation, Pavia, Italy, 6Headache Center Frankfurt, Frankfurt am Main, Germany, 7Headache Unit and Research Group, Vall d’Hebron Hospital and Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain, 8Department of Neurology, Brandenburg Medical School Theodor Fontane, University Hospital Brandenburg/Havel, Brandenburg/Havel, Germany, 9The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 10Teva Pharmaceuticals Europe B.V., Haarlem, The Netherlands, 11Teva GmbH, Ulm, Germany, 12Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany

P43/EP34 Preventive Efficacy of Rimegepant: An Individual Patient Data Meta analysis Across Five Randomized Trials

Richard Lipton1, Anthony Hatswell2, Samuel JK Barnes2, Alexandra Thiry3, Jo Atkinson4, Robert Fountaine3, Denise E. Chou5

1Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, USA, 2Petauri Evidence, Nottingham, UK, 3Pfizer Inc., Groton, USA, 4Pfizer Ltd., Tadworth, UK, 5Pfizer Inc., Cambridge, USA

P44/EP35 Atogepant 60 mg Compared With Topiramate 50, 75, and 100 mg for the Preventive Treatment of Migraine: Dose Subgroup Analysis of the mITT and Double-Blind Treatment Completers Populations of the TEMPLE Study

Brad Klein1, Jan Versijpt2, Cristina Tassorelli3,4, Andrew M. Blumenfeld5, Yingyi Liu6, Krisztian Nagy6, Sophie Musson6, Brett Dabruzzo6, Ivonna Reda6, Uwe Reuter7

1Abington Neurological Associates, Abington, USA, 2Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium, 3Department of Brain and Behavioral Science, University of Pavia, Pavia, Italy, 4Headache Science and Neurorehabilitation Centre, IRCCS C. Mondino Foundation, Pavia, Italy, 5Cedars Sinai Health System, Los Angeles, USA, 6AbbVie Inc., North Chicago, USA, 7Department of Neurology, Charite, Berlin, Germany; University Hospital Bonn, Bonn, Germany

P45/EP36 Adverse Event Profile of Once-daily Rimegepant for Episodic Migraine Prevention: A Pooled Subgroup Analysis of Two Clinical Trials

Dr Jeremias Antinew1, Dr Robert J Fountaine1, Dr Sergey Dubrovin2, Dr Patrizia DeBesi3, Dr Vittorio Loprinzo4, Esther Straghan5

1Pfizer Inc., Groton, USA, 2Pfizer, Moscow, Russia, 3Pfizer S.r.l., Milan, Italy, 4Pfizer Inc., New York, USA, 5Pfizer Ltd., Tadworth, UK

P46/EP37 Pragmatic clinical outcomes of OnabotulinumtoxinA for elderly patients with chronic migraine: a multicenter real-world study

Dr Soo-jin Cho1, Dr Mi-Kyoung Kang1, Dr Soohyun Cho2, Dr Byung-Su Kim3, Dr Hong-Kyun Park4, Dr Yooha Hong1

1Dongtan Sacred Heart Hospital, Hallym University College of Medicine,, Hwaseong, Republic of Korea, 2, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, 3Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea, 4Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea

P47/EP38 Is time well spent providing advice via back to referrer e mails to General Practitioners on migraine management?

Dr George Gorrie1

1NHS Greater Glasgow And Clyde, Glasgow, Scotland

P48 Rimegepant for the Prevention of Migraine in Adults With Inadequate Response to Several Non-Migraine-Specific Oral Preventive Medications By Frequency of Migraine Days at Baseline

Sait Ashina1, Peter McAllister2, Luz Ramirez3, Alexandra Thiry4, Robert Fountaine4, Ulla Sofie Lønberg5

1Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, USA, 2New England Institute for Neurology and Headache, Stamford, USA, 3Pfizer Inc., Princeton, USA, 4Pfizer Inc., Groton, USA, 5Pfizer ApS, Ballerup, Denmark

P49 Longitudinal changes in IHS-defined absolute migraine burden categories over time with fremanezumab: a pooled analysis of the PEARL and FINESSE studies

Messoud Ashina1,2, Gregor Broessner3, Cristina Tassorelli4,5, Charly Gaul6, Patricia Pozo-Rosich7, Lars Neeb8, Dr Paul J. Dorman9, Pinar Kokturk10, Xenia Hamann11, Stefania Zuppone10, Andreas Straube12

P50/EP39 Real-world treatment persistence and adherence with botulinum toxin type A versus anti-CGRP monoclonal antibodies in migraine: a retrospective cohort study from a specialized headache centre

Dr Leilia Zharashueva1, PhD, Professor Margarita Naprienko1

1Sechenov University, Moscow, Russia

P51/EP40 Evaluation of Real-World Treatment Outcomes for Eptinezumab in Migraine Management at a UK Pain Service

Doctor Modar Khalil2, Ria Bhola1, Doctor Kavita Poply1, Professor Vivek Mehta1

1St Bartholomew’s Hospital, City, St Georges & Queen Mary University, London, London, United Kingdom, 2Manchester Centre for Neurosciences, Salford Royal Hospital, Salford, United Kingdom

P52/EP41 Atogepant-Induced DRESS Syndrome: Case Report

Dr Maria Francisca Rocha1, Dr Frederick Vonberg1, 4, Dr Kate Dear1, 2, 3, Dr Priscilla Anketell1, Miss Antoinette Lagratta1, Dr Dheeraj Kalladka1

1Imperial College Healthcare NHS Trust, London, United Kingdom , 2Chelsea and Westminster Hospital , London, United Kingdom , 3Queen Elizabeth Medical Campus , Perth, Australia, 4University College London Hospitals (UCLH) , London, United Kingdom

P53 A post-hoc assessment of the impact of headache-free interictal period duration and every other day treatment with rimegepant on quality of life scores in a 12-week randomized placebo-controlled trial of migraine prevention

Dr Stewart J Tepper1, Dr Mohammad A Chaudhary2, Dr Alexandra Thiry3, Dr Luz M Ramirez4, Sara Ramaker2, Harpreet Seehra5, Dr Joanna Atkinson6, Dr Aaron Jenkins5

1The New England Institute for Neurology and Headache, Stamford, USA, 2Pfizer Inc., Collegeville, USA, 3Pfizer Inc., Groton, USA, 4Pfizer Inc., Princeton, USA, 5Pfizer R&D UK Ltd., Tadworth, UK, 6Pfizer Ltd., Tadworth, UK

P54 Unmet patient needs in migraine prevention: US data from an international survey of real-world impact, preventive medication use and drivers of discontinuation

Shirley Kessel1, Elena Ruiz de la Torre2, Cristina Tassorelli3, Jack Schim4, Jessica Ailani5, Dr Katherine Sommer6, Peter J. Goadsby7

1Miles for Migraine, Jericho, USA, 2European Migraine and Headache Alliance, 3University of Pavia, Pavia, Italy, 4The Neurology Center of Southern California, Carlsbad,, USA, 5Medstar Georgetown University Hospital, Washington DC, USA, 6Ipsen, Cambridge,, USA, 7King Abdullah University of Science and Technology, Saudi Arabia and King’s College London, London, UK

P55 A Mixed-methods Feasibility Trial of Self-Acupuncture for Patients with Migraines (SAM)

Ms Catrina Davy1,2, Professor Michael Loughlin1, Dr John Hughes1,2

1University of West London, London, United Kingdom, 2University College London Hospitals, London, United Kingdom

P56 Early Response Patterns and Long‑Term Clinical Outcomes in Chronic Migraine: A Two‑Year Prospective Study of Individualized Homeopathic Treatment

Dr Spiros Kivellos1

1Centre of Classical Homeopathy, Athens, Greece

P57 An Open-Label Randomized Clinical Trial Comparing Amitriptyline and Propranolol in Migraine Associated with Calcified Neurocysticercosis: Implications for Inflammation-Driven Migraine

Dr Preeti Gupta1, Dr Ravi UniyalL1, Dr Rajesh Verma1, Dr Hardeep Singh Malhotra1, Dr Shweta Pandey1, Dr Imran Rizvi1, Dr Harish Nigam1

1King George’s Medical University, Lucknow, India

P58 Predictors of school attendance in children and adolescents with migraine within a specialist Children’s Headache Clinic: the Great Ormond Street experience

Dr Nazia Karsan1, Dr Gabriele Sebastianelli, Dr Simone Braca, Professor Peter Goadsby, Dr Prab Prabhakar

1Lewisham & Greenwich Nhs Trust/Great Ormond Street Hospital For Children, London, United Kingdom

P59 Premonitory episodes without headache during anti-CGRP preventive treatments: a cross-sectional multicenter study

Dr Gabriele Sebastianelli1,2, Dr. Antonio Munafò3, Dr. Pubudu Amarasena1, Fiona Greenword1, Stefania Maniataki1, Dr. Andrea Burgalassi3, Dr. Francesco De Cesaris3, Dr. PhD David Moreno1, Dr. PhD Francesca Puledda1, Dr. PhD Nazia Karsan1, Prof. Alberto Chiarugi3, Prof. Peter James Goadsby1,4

1NIHR King’s Clinical Research Facility, SLaM Biomedical Research Centre and Wolfson SPaRC, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom, 2Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Sapienza University of Rome, Latina, Italy, 3Headache Center and Clinical Pharmacology Unit, Florence, Italy, 4Division of Biomedical Sciences, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia

P60/EP42 Course of headache frequency across pregnancy: do demographic factors predict trajectory?

Dr Amy Gimson1, Stefania Maniataki1,2, Fiona Greenwood1,2, Dr Argyro Syngelaki3, Professor Kypros Nicolaides3, Professor Peter Goadsby1,2,4, Dr Francesca Puledda1,2

1NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK, 2Department of Neurology, Kings College Hospital, London, UK, 3Foetal Medicine Institute, King’s College Hospital, London, UK, 4King Abdullah University of Science & Technology, Thuwal, Saudi Arabia

P61/EP43 A gap in maternity care: development of a Pregnancy/Migraine Clinical Pathway and Patient Information Leaflet

Ms Fiona Greenwood1,2, Stefania Maniataki1,2, Dr Amy Gimson1, Dr Agyro Syngelaki3, Professor Kypros Nicolaides3, Professor Peter James Goadsby1,2,4, Dr Francesca Puledda1,2

1NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom, 2Department of Neurology, Kings College Hospital, London , United Kingdom, 3Foetal Medicine Institute, Kings College Hospital, London, United Kingdom, 4King Abdullah University of Science & Technology, Thuwal, Saudi Arabia

P62/EP44 Epidemiology of Headache in a Pregnancy Cohort: Use of the ID Migraine screening tool

Ms Stefania Maniataki1,2, Fiona Greenwood1, Dr Amy Gimson2, Dr Argyro Syngelaki3, Professor Kypros Nicolaides3, Dr Francesca Puledda1,2, Professor Peter J. Goadsby1,2,4

1Department of Neurology, King’s College Hospital, London, United Kingdom, 2NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London , United Kingdom, 3Foetal Medicine Institute, King’s College Hospital, London, United Kingdom, 4King Abdullah University of Science & Technology, Thuwal, Saudi Arabia

P63/EP45 Menstrual-related pain symptoms in women with migraine

Dr Sandra Van Der Griend1, Bsc. Fleur Laumen1, Dr. Britt van der Arend1, Prof. Dr. Gisela Terwindt1

1Leiden University Medical Center (LUMC), Leiden, Netherlands

P64/EP46 Prevalence of Migraines in Postmenopause: A Systematic Review and Meta-Analysis

Ms Abbie Greenwood1, Ruth Jensen1, Dr Megan Crawford1, Dr George Gorrie2, Dr Victor Shiramizu1

1University Of Strathclyde, Glasgow, Scotland, 2Queen Elizabeth University Hospital, Glasgow, Scotland

P65 Evaluating the Impact of a Specialized Headache-in-Pregnancy Clinic: A Prospective Study of Patient-Reported Outcomes and Experiences

Hayley Thornton1, Shawna Kelly1, Neurologist William Kingston1

1University Of Toronto, Toronto, Canada

P66 Contralateral biomechanical dysfunction in hypermobility-associated headache: bilateral dynamic ultrasound and scapular kinematic phenotyping in EDS/HSD

Dr Lev Kalika1, Dr Rostyslav Bubnov2

1New York Dynamic Neuromuscular Rehabilitation & Physical Therapy, New York, USA, 2Clinical hospital Pheophania, Kyiv, Ukraine

P67/EP47 Prediction From Sleep Characteristics: Potential Relevance to Headache Disorders

Kylie Vaickus, Dr. Guido Faas, Rebecca Ortiz, Dr. Sinifunanya Nwaobi, Dr. Andrew Charles, Dr Dmitri Yousef Yengej

1UCLA, Los Angeles, USA

P68/EP48 Can Fewer Cases Be Enough? Two Machine Learning Methods (TabPFN Versus XGBoost) for Multiclass Headache Diagnosis

Dr Masahito Katsuki1,2, Dr. Yasuhiko Matsumori4, Dr. Siobhán O’Connor1, Dr. Kieran Moran1,3, Dr. Tomás Ward1

1Dublin City University, Dunblin, Ireland, 2Nagaoka University of Technology, Nagaoka, Japan, 3Maynooth University, Kildare, Ireland, 4Sendai Headache and Neurology Clinic, Sendai, Japan

P69 Machine learning vs. conventional statistics for predicting pain freedom after greater occipital nerve (GON) block in acute migraine

Dr Carlo Lastarria1, Dr PHD Masahito Katsuki2,6, PHD Siobhan O Connor3, PHD Tomas Ward4, PHD Kieran Moran5

1Sanna Clinic, Arequipa, Peru, 2Nagaoka University of Technology, Nagaoka, Japan, 3School of Health and Human Performance, Dublin, Ireland, 4Insight Research Ireland Centre for Data Analytics, Dublin, Ireland, 5Department of Sport Science and Nutrition and Insight Research, Dublin, Ireland, 6Dublin City University, Dublin, Ireland

P70 REM Sleep Detection and Characterization With Deep Learning Models: Potential Utility In Preclinical and Clinical Investigation of Headache Disorders

Kethan Raman1, Dr Guido Faas1, Dr. Andrew Charles1, Dr Dmitri Yousef Yengej1

1Ucla, Los Angeles, USA

P71 A sequence-to-sequence deep learning model for prediction of rodent cerebral blood flow from head movement

Mr. Shrayes Raman1, Dr. Dmitri Yousef-Yengej1, Dr. Guido Faas1, Dr. Andrew Charles1

1University Of California, Los Angeles, Los Angeles, USA

P72/EP49 Defining cluster headache attack recurrence after oxygen treatment: insights from a population-based study

Miss Helin Gosalia1, Dr Diana Y Wei1,2, Professor Peter J Goadbsy1,3

1NIHR King’s Clinical Research Facility, King’s College London, United Kingdom, 2Neurology Department, King’s College Hospital, United Kingdom, 33. Division of Biomedical Sciences, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia

P73/EP50 Breaking the Barrier: Understanding the Postcode Lottery and Formulary Silencing in UK Regional Cluster Headache Care

Dr Ravindra Inaththappulige1,2, Dr Kasun Athukoralage1, Dr Amelia Panavila1, Claire Winstanley1, Carrie Poole1, Irene Jacob1, Dr Brendan Davies1

1University Hospitals Of North Midlands NHS Trust, Stoke on Trent, United Kingdom, 2Kings College London, London, United Kingdom

P74/EP51 Vestibular symptoms in migraine with and without aura: a cohort study

MD Noortje Vosbeek1,2, Dr Nancy van Veelen2, Dr, PhD Meinie Seelen1, Dr, PhD Tjasse Bruintjes1,2, Dr, PhD Gisela Terwindt2

1Apeldoorn Dizziness Centre, Apeldoorn, The Netherlands, 2Leiden University Medical Center, Leiden, The Netherlands

P75/EP52 Constipation in migraine and none-migraine populations: A systematic literature review of epidemiology, clinical, economic and humanistic burden

Masara Elgares1, MSc Selin Rossi2, MPH, BA Kristen Markus2, MBChB Joana Atkinson3, Dr Karin Hygg-Blakeman4, MSc, CPsycho Lucy Abraham1

1Pfizer R&D Ltd UK, Tadworth , United Kingdom , 2Adelphi Values PROVE, Bollington, United Kingdom , 3Pfizer Ltd, Tadworth , United Kingdom , 4Pfizer AB, Sweden

P76 Migraine in America Symptoms and Treatment (MAST) Study: Evaluating Burden and Disability in a Subgroup of Women with Perimenstrual Headache (MAST-MM)

Jelena Pavlovic1, Richard B. Lipton1, Jessica Ailani2, Niki Holtzman-Hayes1, Kristina M. Fanning3, Talia A. Guidi3, Tsz “Tiffany” Chan4, Natty Chalermpalanupap4, Dawn C. Buse1

1Albert Einstein College of Medicine, Bronx, USA, 2Medstar Georgetown University Hospital, Washington, DC, USA, 3MIST Research, Wilmington, USA, 4AbbVie, North Chicago, USA

P77/EP53 Migraine Is Associated with Increased Psychiatric, Vascular, and Female-Specific Comorbidities: A Sex-Stratified Comparison with Controls

Dr Suzanne Viersen1, Drs. Annemijn Oosterlee1, Dr. Nancy van Veelen1, Dr. Britt van der Arend1, Dr. Irene de Boer1, Prof. Dr. Gisela Terwindt1

1Leiden University Medical Centre, Leiden, Netherlands

P78/EP54 Evaluating clinical phenotypes of hemiplegic migraine in paediatric and adult patients

Dr Salman Karsan1,2, Lisa-Marie Rosemeyer1, Professor Peter J Goadsby1,2, Dr Prab Prabhakar3, Dr Nazia Karsan1,2

1King’s College London, London, United Kingdom, 2King’s College Hospital Foundation Trust, London, United Kingdom , 3Great Ormond Street Hospital Foundation Trust, London, United Kingdom

P79/EP55 Vertigo Among Migraine Patients Attending a General Neurology Clinic in Egypt: A Potentially Unrecognised Vestibular Burden

Dr Ahmed Abdalla1,2, Dr Ahmed Elhussieny1, Professor Amal Khafagy1, Professor Nermin Hamdy1, Professor Peter J Goadsby2,3

1Neurology and Psychiatry Department, Faculty of Medicine, Minia University, Minia, Egypt, 2NIHR King’s Clinical Research Facility, King’s College London, London, United Kingdom, 3King Abdullah University of Science & Technology, Thuwal, Saudi Arabia

P80/EP56 Headache severity, beyond headache frequency, is associated with vestibular symptom burden in vestibular migraine

Dr Maria Dolores Villar-Martinez1, Dr Ahmed Abdalla1,3, Caroline Domingos-Belo1, Dr Damla Karaca1, Prof Peter Goadsby1,2

1Wolfson Sparc. Institute of Psychiatry, Psychology and Neurosciences, London, United Kingdom, 2Division of Biomedical Sciences, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, 3Neurology and Psychiatry Department. Minia University, Minia, Egypt

P81 Data-driven vestibular phenotypes in vestibular migraine identified by hierarchical cluster analysis

Dr Maria Dolores Villar-Martinez1, Dr Ahmed Abdalla1,3, Caroline Domingos-Belo1, Dr Damla Karaca1, Prof Peter Goadsby1,2

P82/EP57 Neural correlates of cognitive symptoms in migraine: A resting state fMRI Study

MD Roberta Messina1,2,3, Dr Luca Consuma1,2,3, Dr Alessandro Visentini1,2,3, Dr Federica Genovese1,2,3, Dr, PhD Ilaria Cetta2,3, Dr Alessandro Antoniazzi3, PhD Edoardo Ratto3, Irene Chinali3, Dr, Prof Massimo Filippi1,2,3

1Vita-Salute San Raffaele University, Milan, Italy, 2Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy, 3Headache Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

P83/EP58 Distinct Patterns of Cortical Thickness Alterations in Cluster Headache: A Surface-Based Morphometric Study

Dr Noboru Imai1

1Japanese Red Cross Shizuoka Hospital,

P84 Novel Finding Of Reversible Optic Chiasm Swelling and Signal Change in Spontaneous Intracranial Hypotension (SIH)

Dr Sarah Miller1, Dr George Dickson1, Dr Laura Preston2, Dr Edward Newman1

1Department of Neurology, QEUH , Glasgow, Scotland, 2Department of Neuroradiology, QEUH , Glasgow, Scotland

P85 Service Evaluation of Diagnostic and Management Pathways for Spontaneous Intracranial Hypotension: A Retrospective Study of Single Neurology Centre

Dr Mya Win1, Christopher Farley2, Andrew Rae2, Krishna Dani1

1Department of Neurology, Queen Elizabeth University Hospital, Glasgow., 2Department of Neuro-anaesthesia, Queen Elizabeth University Hospital, Glasgow.,

P86 Patient Global Impression of Change Following Inpatient Treatment for Intractable Migraine

Bradley Torphy1, Director of Research Melody Smith1, Clinical Research Coordinator Chidumebi Ebo, Clinical Research Coordinator Sevda Koseli, Clinical Research Coordinator Sumaiyah Dairo

1Chicago Headache Center & Research Institute, Chicago, United States

P87 Symptoms of Autonomic Dysfunction Amongst Those with Acute Post-traumatic Headache due to Mild Traumatic Brain Injury

Santiago Garza1, Gina Dumkrieger1, Noah Ziff1, Amaal Starling1, Dmitry Esterov2, Kevin Barrett3, Katherine Ross4, Trent Anderson5, Frank Porreca5, Edita Navratilova5, Simona Nikolova1, Jing Li6, Teresa Wu7, Matthew Huentelman8, Catherine Chong1, Todd Schwedt1

1Mayo Clinic, Department of Neurology, Phoenix, United States, 2Mayo Clinic, Department of Physical Medicine and Rehabilitation, Rochester, United States, 3Mayo Clinic, Department of Neurology, Jacksonville, United States, 4Phoenix VA Health Care System, Phoenix, United States, 5University of Arizona, Department of Pharmacology, Tucson, United States, 6Georgia Tech University, School of Industrial and Systems Engineering, Atlanta, United States, 7Arizona State University, School of Computing and Augmented Intelligence, Tempe, United States, 8Translational Genomics Institute, Division of Neurogenomics, Phoenix, United States

Poster presentations

Poster presentations will be displayed for the duration of MTIS2026.

Cookies Policy